Biological ActivityNeuronal nicotinic receptor antagonist that displays selectivity for the α9α10 subtype (IC50 values are 19, 140, 980, 4200 and 7300 nM for α9α10, α6/α3β2β3, α6/α3β4, α3β4 and α3β2 subtypes respectively). Alleviates neuropathic pain in three rat models of human neuropathic pain and accelerates functional recovery of injured neurons.
(Modifications: Cys-16 - C-terminal amide, Disulfide bridge between 2 - 8, 3 - 16)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
A novel α-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo.
Sandall et al.
Are α9α10 nicotinic acetylcholine receptors a pain target for α-conotoxins?
Nevin et al.
Scanning mutagenesis of α-conotoxin Vc1.1 reveals residues crucial for activity at the α9α10 nicotinic acetylcholine receptor
Halai et al.
Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors.
Vincler et al.
Citation for ACV 1
The citations listed below are publications that use Tocris products. Selected citations for ACV 1 include:
1 Citation: Showing 1 - 1
Re-Emergent Inhibition of Cochlear Inner Hair Cells in a Mouse Model of Hearing Loss.
Authors: Zachary and Fuchs
J Neurosci 2015;35:9701
No product specific FAQs exist for this product, however you mayView all Peptide FAQs
Reviews for ACV 1
There are currently no reviews for this product. Be the first to review ACV 1 and earn rewards!
Have you used ACV 1?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image